All articles tagged with #petrelintide
Zealand Pharma's stock rose 17% after announcing that its experimental weight loss drug petrelintide showed similar efficacy to Ozempic with fewer side effects in a phase 1 trial. Petrelintide, a long-acting amylin analog, could be an alternative for patients who can't tolerate GLP-1 treatments.
Zealand Pharma's shares surged 18% after positive early-stage trial results for its weight loss drug petrelintide, which showed an average body weight reduction of 8.6% compared to 1.7% with a placebo. The drug was deemed safe and well-tolerated, positioning it as a potential alternative to GLP-1 receptor agonist-based therapies like Novo Nordisk's Ozempic. The company plans to proceed with a phase 2 clinical trial.